AU2004292416B2 - Method of decreasing fat deposits and body weight in mammals and birds - Google Patents

Method of decreasing fat deposits and body weight in mammals and birds Download PDF

Info

Publication number
AU2004292416B2
AU2004292416B2 AU2004292416A AU2004292416A AU2004292416B2 AU 2004292416 B2 AU2004292416 B2 AU 2004292416B2 AU 2004292416 A AU2004292416 A AU 2004292416A AU 2004292416 A AU2004292416 A AU 2004292416A AU 2004292416 B2 AU2004292416 B2 AU 2004292416B2
Authority
AU
Australia
Prior art keywords
salbutamol
isomer
mammal
beta
bird
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004292416A
Other languages
English (en)
Other versions
AU2004292416A1 (en
Inventor
Gunnar A. K. Aberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALTERAGON Pty Ltd
Original Assignee
ALTERAGON Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALTERAGON Pty Ltd filed Critical ALTERAGON Pty Ltd
Publication of AU2004292416A1 publication Critical patent/AU2004292416A1/en
Application granted granted Critical
Publication of AU2004292416B2 publication Critical patent/AU2004292416B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
AU2004292416A 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds Ceased AU2004292416B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52437603P 2003-11-20 2003-11-20
US60/524,376 2003-11-20
US10/987,665 2004-11-12
PCT/US2004/037966 WO2005051092A2 (en) 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds
US10/987,665 US20050113456A1 (en) 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds

Publications (2)

Publication Number Publication Date
AU2004292416A1 AU2004292416A1 (en) 2005-06-09
AU2004292416B2 true AU2004292416B2 (en) 2010-01-28

Family

ID=34595131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004292416A Ceased AU2004292416B2 (en) 2003-11-20 2004-11-12 Method of decreasing fat deposits and body weight in mammals and birds

Country Status (8)

Country Link
US (2) US20050113456A1 (enExample)
EP (1) EP1684593A4 (enExample)
JP (1) JP2007515402A (enExample)
AU (1) AU2004292416B2 (enExample)
CA (1) CA2545559A1 (enExample)
NZ (1) NZ547178A (enExample)
WO (1) WO2005051092A2 (enExample)
ZA (1) ZA200604077B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
US20070264313A1 (en) * 2006-05-12 2007-11-15 Musser Robert E Methods and compositions relating to animal dietary acids
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
AU2008331928B2 (en) 2007-12-03 2012-08-16 Bridge Pharma, Inc. Use of RR/SR-ractopamine
MY159212A (en) 2008-09-02 2016-12-30 Nutricia Nv Nutritional compositions with coated lipid globules
WO2010068086A1 (en) 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
MX2012008171A (es) * 2010-01-15 2012-12-17 Lithera Inc Formulaciones aglomeradas liofilizadas.
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
EP2646012A4 (en) 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT
BR112016009351B1 (pt) 2013-11-01 2020-12-22 N.V. Nutricia Uso de lipídio para a preparação de uma composição nutricional e fórmula para recémnascidos
KR102273533B1 (ko) * 2015-06-15 2021-07-06 삼성전자 주식회사 무선 통신 시스템에서 서비스 제공 방법 및 장치
PL3574771T3 (pl) 2015-10-15 2023-03-13 N.V. Nutricia Preparat do początkowego żywienia niemowląt mający specjalną architekturę lipidów do pobudzania zdrowego wzrostu
MY196605A (en) 2016-12-09 2023-04-20 Nutricia Nv Nutritional Composition for Improving Cell Membranes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186796A (en) * 1986-02-19 1987-08-26 Glaxo Group Ltd Veterinary preparations containing salbutamol

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0085514A3 (en) * 1982-01-28 1984-02-29 Beecham Group Plc Compositions comprising a beta-antagonist and a beta-agonist, their preparation, and their use in treating obese humans and animals
US5147869A (en) * 1986-12-11 1992-09-15 Roussel Uclaf Zootechnical compositions
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US5541188A (en) * 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US5530029A (en) * 1987-09-15 1996-06-25 The Rowett Research Institute Therapeutic applications of clenbuterol
FR2642075B1 (fr) * 1989-01-25 1991-04-26 Pasteur Institut Polypeptides ayant une activite de recepteur (beta)-adrenergique chez l'homme, impliques dans la reponse lipolytique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substance active sur ces polypeptides
DK339289D0 (da) * 1989-07-07 1989-07-07 Dak Lab As Farmaceutisk praeparat
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
WO1991009596A1 (en) * 1990-01-05 1991-07-11 Sepracor, Inc. Optically pure r(-) albuterol for treating asthma
JP3358631B2 (ja) * 1993-05-17 2002-12-24 三菱瓦斯化学株式会社 メタノ−ルの脱水素方法
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5399765A (en) * 1994-05-23 1995-03-21 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5698199A (en) * 1995-03-10 1997-12-16 Kao Corporation Lipolysis acceleration method
US5708036A (en) * 1996-01-29 1998-01-13 Pesterfield, Jr.; E. Charles Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
AU737608B2 (en) * 1997-04-30 2001-08-23 Courage Corporation Pty Ltd Composition and methods using an eutomer
US7767708B2 (en) * 1998-11-04 2010-08-03 Schering-Plough Animal Health Corp. Growth stimulant compositions
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
GB0030171D0 (en) * 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186796A (en) * 1986-02-19 1987-08-26 Glaxo Group Ltd Veterinary preparations containing salbutamol

Also Published As

Publication number Publication date
US20080020019A1 (en) 2008-01-24
US20050113456A1 (en) 2005-05-26
JP2007515402A (ja) 2007-06-14
NZ547178A (en) 2008-06-30
EP1684593A4 (en) 2010-02-10
WO2005051092A2 (en) 2005-06-09
WO2005051092A3 (en) 2006-04-06
CA2545559A1 (en) 2005-06-09
ZA200604077B (en) 2009-11-29
EP1684593A2 (en) 2006-08-02
AU2004292416A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
US20080020019A1 (en) Method of decreasing fat deposits and body weight in mammals and birds
AU2008331928B2 (en) Use of RR/SR-ractopamine
US8445542B2 (en) Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals
CA2039194C (en) Uses of l-deprenyl and compositions for same
AU737608B2 (en) Composition and methods using an eutomer
JP2007515402A5 (enExample)
EP0662324A1 (en) Use of beta-adrenergic agonists for treating loss of function of striated muscles
JP6209208B2 (ja) ブロイラー鶏の性能向上法
US20080070990A1 (en) Use of ractopamine enantiomers
CN109068685B (zh) 含有日香木苷和/或夜香树苷的动物饲料添加剂
EP1787529A2 (en) Composition and methods using an eutomer
MXPA99009783A (en) Composition and methods using an eutomer
CN1882320A (zh) 减少哺乳动物和鸟类的脂肪堆积物和体重的方法
WO2009020620A1 (en) Synergisms between repartitioning and immunomodulating compounds
TWI301412B (en) Pharmaceutical composition and injection solution for improving the well-being of poultry
THEJOMOORTHY STUDIES ON THE EFFECT OF CERTAIN GROWTH PROMOTING AGENTS IN RABBITS FOR MEAT AND WOOLf HAIR PRODUCTION
HK1011611B (en) Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired